Preclinical studies with FcγR bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER- 2/neu overexpressing breast cancer

Cancer Research

Volumn 57, Issue 4, 1997, Pages 696-701

  Stockmeyer, Bernhard ^a   Valerius, Thomas ^a   Repp, Roland ^a   Heijnen, Ingmar A F M ^d   Bühring, Hans Jörg ^b   Deo, Yashwant M ^c   Kalden, Joachim R ^a   Gramatzki, Martin ^a   Van de Winkel, Jan G J ^d  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c MEDAREX INC   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; CELL KILLING; COMPLEMENT ACTIVATION; CYTOLYSIS; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NEUTROPHIL; PHAGOCYTOSIS; PRIORITY JOURNAL; TUMOR GROWTH;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BREAST NEOPLASMS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; RECEPTOR, ERBB-2; RECEPTORS, IGG; TUMOR CELLS, CULTURED;

EID: 0031053094     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Harris, J. R., Lippman, M. E., Veronesi, U., and Willett, W. Breast cancer. N. Engl. J. Med., 327: 319-328, 390-398, 473-480, 1992.
2. Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J., and the German Cancer Aid 17-1A Study Group. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 243: 1177-1183, 1994.
3. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
4. Ullrich, A., and Schlessinger, J. Signal transduclion by receptors with tyrosine kinase activity. Cell, 61: 203-212, 1990.
5. HER2 monoclonal antibody in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol., 14: 737-744, 1996.
6. Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V., Deo, Y., Graziano, R., Fisher, J. L., Meyer, L., Mrozek-Orlowski, M., Wardwell, K., Guyre, V., Morley, T. L., Arvizu, C., and Fanger, M. W. Phase Ia/Ib trial of bispecific antibody MDX-210 (anti-Her-2/neu X anti-FcγRI) in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J. Clin. Oncol., 13: 2281-2292, 1995.
7. Weiner, L. M., Clark, J. I., Davey, M., Li, W. S., de Palazzo, I. G., Ring, D. B., and Alpaugh, R. K. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res. 55: 4586-4593, 1995.
8. Dillman, R. O. Antibodies as cytotoxic therapy. J. Clin. Oncol., 12: 1497-1515, 1994.
9. Lieschke, G. J., and Burgess, A. W. Drug therapy: granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (I+II). N. Engl. J. Med., 327: 28-35, 99-106, 1992.
10. Valerius, T., Repp, R., de Wit, T. P. M., Berthold, S., Platzer, E., Kalden, J. R., Gramatzki, M., and Van de Winkel, J. G. J. Involvement of the high affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood, 52: 931-939, 1993.
11. Van de Winkel, J. G. J., and Capel, P. J. A. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today, 14: 215-221, 1993.
12. Guyre, P. M., Morganelli, P. M., and Miller, R. Recombinant immune interferon increases immunoglobulin Fc receptors on cultured human mononuclear phagocytes, J. Clin. Invest., 72: 393-397, 1983.
13. Repp, R., Valerius, T., Sendler, A., Gramatzki, M., Iro, H., Kalden, J. R., and Platzer, E. Neutrophils express the high affinity receptor for IgG (FcγRI; CD64) after in vivo application of rhG-CSF. Blood, 78: 885-889, 1991.
14. Fanger, M. W., Shen, L., Graziano, R. F., and Guyre, P. M. Cytotoxicity mediated by human Fc receptors for IgG. Immunol. Today, 10: 92-99, 1989.
15. Deo, Y. M., Graziano, R. F., Repp, R., and Van de Winkel, J. G. J. Clinical significance of IgG receptors and FcγR-directed immunotherapies. Immunol. Today, in press, 1997.
16. Colombo, M. P., Ferrari, G., Stoppacciaro, A., Parenza, M., Rodolfo, M., Mavilio, F., and Parmiani, G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med., 173: 889-897, 1991.
17. Midorikawa, Y., Yamashita, T., and Sendo, F. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo. Cancer Res., 50: 6243-6247, 1990.
18. Matsumoto, Y., Saiki, I., Murata, J., Okuyama, H., Tamura, M., and Azuma, I. Recombinant human granulocyte colony-stimulating factor inhibits the metastasis of hematogenous and non-hematogenous tumors in mice. Int. J. Cancer, 49: 444-449, 1991.
19. Lichtenstein, A. Granulocytes as possible effectors of tumor immunity. In: H. F. Oettgen (ed.), Human Cancer Immunology, Vol. 1, pp. 731-746. Philadelphia: W. B. Saunders, 1990.
20. Elsässer, D., Valerius, T., Repp, R., Weiner, G. J., Deo, Y., Kalden, J. R., Van de Winkel, J. G. J., Stevenson, G. T., Glennie, M. J., and Gramatzki, M. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with G-CSF. Blood, 87: 3803-3812, 1996.
21. Cemerlic, D., Dadey, B., Han, T., and Vaickus, L. Cytokine influence on killing of fresh chronic lymphocytic leukemia cells by human leukocytes. Blood. 77: 27072715, 1991.
22. r 200,000 glycoprotein selectively associated with human breast cancer. Cancer Res., 49: 3070-3080, 1989.
23. Fendly, B. M., Winget, M., Hudziak, R. M., Lipari, M. T., Napier, M. A., and Ullrich, A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res., 50: 1550-1558, 1990.
24. HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood, 86: 1916-1923, 1995.
25. Guyre, P. M., Graziano, R. F., Vance, B. A., Morganelli, P. M., and Fanger, M. W. Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J. Immunol., 143: 1650-1655, 1989.
26. Looney, R. J., Abraham, G. N., and Anderson, C. L. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J. Immunol., 136: 1641-1647, 1986.
27. Fleit, H. B., Wright, S. D., and Unkeless, J. C. Human neutrophil Fcg receptor distribution and structure. Proc. Natl. Acad. Sci. USA, 79: 3275-3279, 1982.
28. Greenman, J., Tutt, A. L., George, A. J. T., Pulford, K. A. F., Stevenson, G. T., and Glennie, M. J. Characterization of a new monoclonal antibody. AT10, and its incorporation into a bispecific F(ab′)2 derivative for recruitment of cytotoxic effectors. Mol. Immunol. 28: 1243-1254, 1991.
29. Zipf, T. F., Lauzon, G. J., and Longenecker, B. M. A monoclonal antibody detecting a 39,000 MW molecule that is present on B lymphocytes and chronic lymphocytic leukemia cells but is rare on acute lymphocytic leukemia blasts. J. Immunol., 131: 3064-3072, 1983.
30. 3 antibody derivatives. In: G. Gallagher, R. C. Rees, and C. W. Reynolds (eds.), Tumour Immunobiology, A Practical Approach, pp. 225-244, Oxford: Oxford University Press. 1995.
31. Gosselin, E. J., Brown, M. F., Anderson, C. L., Zipf, T. F., and Guyre, P. M. The monoclonal antibody 41H16 detects the Leu 4 responder form of human FcγRII J. Immunol., 144: 1817-1822, 1990.
32. Osborne, J. M., Chacko, G. W., Brandt, J. T., and Anderson, C. L. Ethnic variation in frequency of an allelic polymorphism of human FcyRIIA determined with allele specific oligonucleotide probes. J. Immunol. Methods, 173: 207-217, 1994.
33. Valerius, T., Repp, R., Kalden, J. R., and Platzer, E. Effects of IFN on human eosinophils in comparison with other cytokines; a novel class of eosinophil activators with delayed onset of action. J. Immunol., 145: 2950-2958, 1990.
34. Wee, S. L., Colvin, R. B., Phelan, J. M., Preffer, F. I., Reichert, T. A., Berd, D., and Cosimi, A. B. Fc receptor for mouse IgG1 (FcγRII) and antibody-mediated clearance in patients treated with Leu2a antibody. Transplantation, 48: 1012-1017, 1989.
35. Lund-Johansen, F., Olweus, J., Symington, F. W., Arli, A., Thompson, J. S., Vilella, R., Skubitz, K., and Horejsi, V. Activation of human monocytes and granulocytes by monoclonal antibodies to glycosylphosphatidylinositol-anchored antigens. Eur. J. Immunol., 23: 2782-2791, 1993.
36. Van de Winkel, J. G. J., and Anderson, C. L. CD32 cluster workshop report. In: S. Schlossman et al. (eds.). Leukocyte Typing, Vol. 5, pp., 823-826. Oxford: Oxford University Press, 1995.
37. Daeron, M., Latour, S., Malbec, O., Espinosa, E., Pina, P., Pasmans, S., and Fridman, W. H. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity, 3: 635-646, 1995.
38. Brooks, D. G., Qiu, W. Q., Luster, A. D., and Ravetch, J. V. Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J. Exp. Med., 770: 1369-1385, 1989.
39. Cassel, D. L., Keller, M. A., Surrey, S., Schwartz, E., Schreiber, A. D., Rappaport, E. F., and McKenzie, S. E. Differential expression of FcγRIIA, FcyRIIB and FcyRIIC in hematopoietic cells: analysis of transcripts. Mol. Immunol., 30: 451-460, 1993.
40. Weiner, L. M., Alpaugh, R. K., Amoroso, A. R., Adams, G. P., Ring, D. B., and Barth, M. W. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human FcγRIII- Cancer Immunol. Immunother., 42: 141-150, 1996.
41. Valerius, T., Repp, R., Wieland, G., Deo, Y., Van de Winkel, J. G. J., Kalden, J. R., Lang, N., and Gramatzki, M. Bispecific antibody MDX210 (FcγRI × HER-2/neu) in combination with G-CSF: results of a phase I trial in patients with metastatic breast cancer (Abstract). Proc. Am. Soc. Clin. Oncol., 15: 108, 1996.
42. Weber, J. S., Spears, L., Deo, Y., and Link, J. L. Phase 1 study of a HER-2/neu bispecific antibody with G-CSF in patients with metastatic breast cancer (Abstract). Proc. Am. Soc. Clin. Oncol., 75: 354, 1996.